Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

ANTHELIOS LOTION CORPS ULTRA-FLUIDE - Health Canada Drug Approval Details

Approvals/Health Canada/ANTHELIOS LOTION CORPS ULTRA-FLUIDE

Authorized

STANDARD

ANTHELIOS LOTION CORPS ULTRA-FLUIDE

laboratoires la roche-posay canada🇨🇦 Health Canada

Approval Date: Jul 4, 2025
Approval ID: 42d5fe64a22602a2
Company: laboratoires la roche-posay canada
Type: Standard

Approval Details

Approval Id: 42d5fe64a22602a2
Drug Approval Canada Name: ANTHELIOS LOTION CORPS ULTRA-FLUIDE
Product Name: ANTHELIOS LOTION CORPS ULTRA-FLUIDE
Status: Cancelled Post Market
Status Date: 2019-04-01
Original Market Date: 2017-10-24
Din: 02459515
Drug Class: Human
Dosage Form: Cream
Route Of Administration: Topical
Schedule: OTC
Ahfs: 84:80.00
Atc Original: D02BA30 COMBINATIONS OF PROTECTIVES AGAINST UV-RADIATION
Atc Name: d 02 ba 30
Aig Number: 0652878001
Company Name: laboratoires la roche-posay canada
Company Address: 4895 Hickmore, Montreal, Quebec, Canada, H4T 1K5

Active Ingredients

OCTISALATE

5 % / W/W

AVOBENZONE

3 % / W/W

HOMOSALATE

10 % / W/W

TEREPHTHALYLIDENE DICAMPHOR SULFONIC ACID

2 % / W/W

OCTOCRYLENE

5 % / W/W

OXYBENZONE

6 % / W/W

Authorized

Quick Info

Agency

Health Canada

Country

🇨🇦

Approval Date

Jul 4, 2025

Approval ID

42d5fe64a22602a2

Type

Standard

Back to Health Canada Approvals